US7473241013 - Common Stock
PYXIS ONCOLOGY INC
NASDAQ:PYXS (9/28/2023, 7:09:21 PM)
After market: 2.0016 -0.04 (-1.88%)2.04
+0.2 (+10.87%)
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 72 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing a multi-modality portfolio of therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company has developed a portfolio that includes antibody drug conjugate (ADC), product candidates, immuno-oncology (IO), product candidates, and monoclonal antibody (mAb), preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. Its product pipelines include PYX-201, PYX-106 and PYX-107. Its ADC product candidate is PYX-201, an investigational, novel ADC consisting of an Immunoglobulin G1 (IgG1), anti-fibronectin Extradomain-B, mAb site-specifically conjugated to an auristatin derivative via a cathepsin B-cleavable linker. Its IO product candidate is PYX-106, an investigational, fully human IgG1 isotype Siglec-15-targeting antibody designed to block Siglec-15 mediated suppression of T-cell proliferation and function.
PYXIS ONCOLOGY INC
321 Harrison Avenue, 11th Floor, Suite 1
Boston MASSACHUSETTS
P: 16174533596.0
Employees: 72
Website: https://pyxisoncology.com/
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation...
/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of...
Pyxis Oncology (PYXS) CEO and president Lara Sullivan disclosed in an SEC filing on Monday after the bell a sale of 8,641 shares of the company at prices ranging from $2.1 and $2.25...
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation...
Here you can normally see the latest stock twits on PYXS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: